Jonas Löfgren
(The following information was supplied by the firm)
I am a founding partner of Westerberg and joined the team in 2008 from another law firm, before we formed Westerberg in 2019.
I am an experienced lawyer with a keen and firm interest in the sectors within which I work. I maintain a high degree of personal attention to matters, and I believe in straightforward communication with clients. The team and I are one of few regulatory groups in Sweden.
I have worked with Life Sciences and related highly-regulated sectors such as alcohol, tobacco, foodstuffs and chemicals since 2002, covering all regulatory matters and commercial contract issues, with a particular focus on market access, including pricing and reimbursement and related negotiations, classification and regulatory litigation. I also do a fair bit of product safety and product liability outside the above-mentioned sectors. A significant part of my work further relates to IP commercial matters within my areas of expertise, such as IP-focused transactions.
Recent work highlights include negotiating several acquisitions of multijurisdictional product portfolios of OTC brands and hygiene products for a Swedish client. I have also worked a great deal on matters relating to healthcare apps, such as classification and implementation, as well as patient data issues.
I am co-managing partner of Conférence Bleue, a leading network of European law firms specializing in pharmaceutical, health-care and medical regulatory law. I am also a member of DIA (Drug Information Association).
I regularly provide content to newsletters and magazines.
Recent recognition includes:
Listed by Who’s Who Legal for Life Sciences Regulatory, Transactions and Product Liability
Recommended in transactions by IAM Patent 1000 as a person who “pairs his encyclopaedic knowledge of regulatory law with a resolutely commercial outlook to draft contracts that transform the sectors in which his patrons operate” (2021) and “possesses deep regulatory knowledge, which he also employs to good use when putting together IP-rich deals for prominent industry players.” (2022).